The global critical care diagnostics market size was valued at USD 1.17 billion in 2022 and is anticipated to grow at a compound annual growth rate (CAGR) of 4.9% from 2023 to 2030. The increasing prevalence of chronic diseases, including cardiovascular diseases, respiratory disorders, and cancer, has stimulated the demand for critical care diagnostics. The accurate and timely diagnosis of these conditions is crucial for optimal treatment and effective patient management. In addition, advancements in diagnostic technologies have brought about a significant transformation in critical care diagnostics. The introduction of innovative techniques and devices, such as molecular diagnostics, next-generation sequencing, and advanced imaging modalities, has enhanced the precision, efficiency, and speed of diagnostic tests, ultimately resulting in improved patient outcomes.
The market was significantly affected by the COVID-19 pandemic. This global health crisis placed immense pressure on healthcare systems worldwide and heightened the need for quick and precise diagnostic testing in critical care environments. During the initial stages of the pandemic, there was a surge in demand for diagnostic tests such as Polymerase Chain Reaction (PCR) and antigen tests, which are vital in identifying and confirming COVID-19 infections among critically ill patients. Consequently, there was a substantial rise in the requirement for critical care diagnostic products and services. Moreover, the COVID-19 pandemic underscored the significance of point-of-care testing (POCT) within critical care settings. POCT facilitates rapid testing and provides immediate results, empowering healthcare professionals to make timely decisions regarding patient management. Hence, there was an increasing focus on the development and adoption of innovative POCT devices for critical care diagnostics.
The critical care market, which provides goods and services for patients with life-threatening conditions, was significantly impacted by the COVID-19 pandemic. As more patients require intensive care, there is a rising demand for critical care equipment like ventilators, monitors, and infusion pumps. However, the manufacturers of these devices faced difficulties due to supply chain disruptions, lockdown procedures, and travel restrictions. The COVID-19 pandemic also brought attention to the critical care industry's need for innovation and digitalization, including telemedicine, remote monitoring, and artificial intelligence. These innovations have a potential of reducing the risk of infections and burnout among medical personnel while enhancing the effectiveness and quality of critical care delivery.
Critical care diagnostics is essential for the timely and accurate diagnosis of life-threatening conditions in intensive care units. The increase in the geriatric population and rising critical health conditions and diseases are the key drivers for market growth. Critical care diagnostics include various tests and devices that measure vital signs, blood gases, electrolytes, organ functions, infections, and other parameters. It helps clinicians to monitor and adjust the treatment of critically ill patients, as well as to prevent complications and improve outcomes. According to a report by the Centers for Disease Control (CDC) in 2020, total emergency department visits were 131.3 million, out of which 3.1 million resulted in admission to critical care unit in the U.S. These usually were caused by heart conditions such as heart attack, cardiac arrest, severe burns, serious bleeding, kidney failure, and serious injuries.
The expanding elderly population serves as an important catalyst for the growth of the market. Geriatric individuals display significant vulnerability to chronic diseases and require specialized care. Consequently, the escalating global geriatric population has created a greater need for diagnostic tests in critical care settings. Moreover, point-of-care testing (POCT) has witnessed increasing popularity within critical care environments due to its convenience and swift outcomes. POCT enables immediate diagnosis and facilitates bedside decision-making, reducing the time and resources used on laboratory testing. The demand for POCT devices is projected to grow significantly, propelling the growth of the market.
On the basis of type, the market is categorized into routine and special chemistry, flow cytometry, hematology, immunoproteins, microbial and infectious diseases, coagulation, and others. The immunoproteins segment dominated the market with the largest revenue share of 36.1% in 2022. Immunoproteins are amino acids that function in the immune system, a system of biological functions that guards an organism against disease. The immune system can detect and respond to various pathogens, such as bacteria, viruses, parasites, fungi, cancer cells, and foreign objects. Immunoproteins are involved in both the innate immune system and the adaptive immune system of the immune system, and they can be classified into different types, such as antibodies, cytokines, complement proteins, and major histocompatibility complex proteins.
The microbial and infectious disease segment is expected to grow at the fastest CAGR of 5.5% over the forecast period from 2023 to 2030. These diseases are caused by microorganisms such as bacteria, viruses, parasites, and fungi. Diseases such as HIV, flu, measles, and COVID-19 are examples of microbial and infectious diseases. The segment growth is majorly driven by factors, such as clinical chemistry, flow cytometry tests, and coagulation tests, among others. Moreover, microbiology, infectious tests, and immunoproteins assays are estimated to drive segment growth over the forecast period.
The hematology segment is expected to grow at a lucrative CAGR over the forecast period owing to constant innovative and advanced product launches by market players. For instance, in May 2023, Siemens Healthcare GmbH, a medical devices company based in Germany, announced the launch of two new innovative hematology analyzers: the Atellica HEMA 580 and 570 Analyzers. The analyzers provide user-friendly interfaces and seamless connectivity to multiple analyzers, enhancing workflow efficiency and rapid throughput. These analyzers are designed to eliminate obstacles in the laboratory workflow, enabling streamlined operations and accelerated processing of samples.
On the basis of end use, the market has been segmented into operation rooms, intensive care units, emergency rooms, and others. The emergency rooms segment dominated the market with the largest revenue share of 33.0% in 2022 and is also expected to grow at the fastest CAGR of 5.6% over the forecast period from 2023 to 203. This can be attributed to the prevalence of chronic diseases such as heart strokes, heart attacks, kidney failure, and a rise in mental issues such as anxiety, depression, and other disorders.
The intensive care unit segment is expected to grow at a lucrative CAGR during the forecast period owing to the increasing prevalence of chronic conditions in the U.S. According to the U.S. Department of Health & Human Services, the average ICU occupancy rate in the U.S. was 76.3% as of December 2022. This means that out of 79,271 staffed ICU beds in the country, 60,503 were occupied by patients, of which 12,345 were COVID-19 cases.
North America dominated the critical care diagnostics market with the largest revenue share of 43.0% in 2022, owing to better healthcare infrastructure, more healthcare spending, and better technological acceptance. According to America Medical Association, the U.S. spent USD 4.3 trillion on healthcare, which equates to USD 12,194 per capita. The overall health spending was around 18.3% of the GDP in the same year.
Asia Pacific is expected to grow at the fastest CAGR of 6.9% over the forecast period from 2023 to 2030 due to the high patient population, rising healthcare awareness, increasing investment in healthcare, and various government initiatives. Pneumonia is one of the largest infectious diseases which causes death in children globally. According to the World Health Organization (WHO), it accounts for 14% of deaths in children under five years, killing 740,180 children in 2019. Southern Asia and sub-Saharan Africa toll for the highest number of deaths in children due to pneumonia.
The increasing prevalence of diseases such as pneumonia in the Asia Pacific countries is one of the major factors driving the demand for diagnostics in critical care settings. In addition, various healthcare organizations are undertaking strategic activities such as innovative product and service launches to gain a competitive advantage, resulting in an increasing demand for critical care diagnostics. For instance, in August 2019, Brains Super Speciality Hospital, a provider of complete care for a wide range of health conditions specializing in neurosurgery and brain care, announced the launch of advanced operating suites at BR Life SSNMC Hospital. The operation theatre complex features dedicated operating rooms equipped with state-of-the-art technology to ensure the safety and efficacy of brain and spine surgeries. This complex comprises independent operating suites designed to meet the specific requirements of these specialized procedures. The operating theatre is versatile, facilitating both micro-surgery and simultaneous cerebrovascular intervention. This dual-purpose capability provides a sophisticated operating environment and includes a compact cerebral angiography suite for precise imaging during procedures.
The rise in competition is leading to rapid technological advancements, and companies are constantly working towards improving their products with a major focus on research and development. Factors such as investment in research & development, compliance with regulatory policies, and technological advancements constantly drive the introduction of novel techniques. These companies are engaged in technological advancements, new product development, joint ventures, partnerships, and collaborations to maintain their position in the industry. For instance, in May 2023, F. Hoffmann-La Roche Ltd, a provider of diagnostics and pharmaceutical services based in Switzerland, announced the launch of the Institute of Human Biology (IHB) with a primary focus on advancing research in the domain of human model systems, specifically organoids. By capitalizing on the potential of human model systems, the institute aims to advance the drug discovery and development process by enhancing our comprehension of organ functionality and disease progression. Ultimately, these endeavors will contribute to the accelerated delivery of medications to patients. Additionally, these initiatives will enable early-stage assessments to determine the safety of drug candidates and identify the most effective molecules tailored to individual patients.
Similarly, in May 2023, Abbott, a provider of generic pharmaceutical, nutrition, medical device, and diagnostic products, announced a collection of new programs as part of its extensive multi-million-dollar initiative to enhance diversity in clinical trials and enhance healthcare outcomes for underrepresented populations. These newly introduced components of Abbott's Diversity in Clinical Trials initiative expand upon existing partnerships, scholarships, and the company's commitment to involving diverse participants in its clinical trials, established during the first year of the initiative. Some of the initiatives include the introduction of various programs, including a partnership with the Norton Healthcare Foundation to establish and execute sustainable clinical research models in conjunction with the Institute for Health Equity, a division of Norton Healthcare located in Kentucky, U.S. Additionally, a novel training program for clinical research coordinators has been established through a partnership with Barnett International. Furthermore, Abbott has established a dedicated Diversity in Research Office to promote inclusive participation in clinical trials, ensuring diverse representation across the research landscape. Some of the prominent key industry players operating in the global critical care diagnostics market include:
F. Hoffmann-La Roche Ltd
Siemens Healthcare Private Limited
Chembio Diagnostics, Inc.
Market size value in 2023
USD 1.23 billion
Revenue forecast 2030
USD 1.72 billion
CAGR of 4.9% from 2023 to 2030
Base year for estimation
2018 - 2021
2023 - 2030
Revenue in USD million/billion and CAGR from 2023 to 2030
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Type, end-use, region
North America; Europe; Asia Pacific; Latin America; Middle East & Africa
U.S.; Canada; U.K.; Germany; France; Italy; Spain; Denmark; Sweden; Norway; Japan; China; India; Australia; South Korea; Thailand; Brazil; Mexico; Argentina; Saudi Arabia; South Africa; UAE; Kuwait
Key companies profiled
Abbott; Danaher; F. Hoffmann-La Roche Ltd; BD; EKF Diagnostics; bioMérieux, Inc.; Siemens Healthcare Private Limited; Chembio Diagnostics, Inc.; Bayer AG
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global critical care diagnostics marketreport on the basis of type, end-use, and region:
Type Outlook (Revenue in USD Million, 2018 - 2030)
Routine & Special Chemistry
Microbial & Infectious Disease
End-use Outlook (Revenue in USD Million, 2018 - 2030)
Intensive Care Unit
Regional Outlook (Revenue in USD Million, 2018 - 2030)
Middle East & Africa
b. The global critical care diagnostics market size was estimated at USD 1.17 billion in 2022 and is expected to reach USD 1.23 billion in 2023.
b. The global critical care diagnostics market is expected to grow at a compound annual growth rate of 4.9% from 2023 to 2030 to reach USD 1.72 billion by 2030.
b. North America dominated the critical care diagnostics market with a share of 42.9% in 2022. This is attributable to the strong geographic presence of key players in the U.S.
b. Some key players operating in the critical care diagnostics market include Abbott Laboratories; Beckman-Coulter; Roche Diagnostics; Becton Dickinson & Co; EKF Diagnostics Holding plc; Chembio Diagnostic systems. Inc.; Bayer Healthcare AG; bioMerieux Inc; and Siemens Healthineers.
b. Key factors that are driving the critical care diagnostics market growth include the recognition and increasing awareness of targeted therapy as an alternative to unnecessary drug prescriptions, the increasing geriatric population, and telehealth and remote communications between diagnostics and laboratories.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
"The quality of research they have done for us has been excellent."